Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Gov't to Study Stronger Protection of NDA Data
July 7, 2003
- ADR Reports Hit Record High, Totaling 28,416 in FY2002
July 7, 2003
- Yamanouchi Fails to Report ADRs of Gaster 10 by Legal Deadline
July 7, 2003
- REGULATORY NEWS IN BRIEF
July 7, 2003
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 7, 2003
- Meet the Leaders (22)
July 7, 2003
- CORPORATE ROUNDUP NEWS IN BRIEF
July 7, 2003
- WORLD NEWS IN BRIEF
July 7, 2003
- NEW PRODUCTS
July 7, 2003
- Sankyo Reports Good Results with e-Promotion
July 7, 2003
- PRESS SEMINAR
July 7, 2003
- FJPWA Study Team Proposes Model PMS Manual
July 7, 2003
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
July 7, 2003
- BUSINESS NEWS IN BRIEF
June 30, 2003
- FPMAJ Committee Proposes Revisions to NHI Pricing Rules
June 30, 2003
- Business Challenges Discussed: UBS Conference
June 30, 2003
- Meet the Leaders (21)
June 30, 2003
- DIAGNOSTIC NEWS IN BRIEF
June 30, 2003
- MEDICAL DEVICE NEWS IN BRIEF
June 30, 2003
- OTC NEWS IN BRIEF
June 30, 2003
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…